NEWSLETTER
Your exclusive source
of ATMP insights and updates
Stay updated on ATMP innovation and rare disease care across Europe
Have you heard about CREATIC LabtoP Talks ~ From Lab to Patient?
On November 22, 2024, the CREATIC team hosted the very first LabtoP Talk – a conversation on how Advanced Therapy Medicinal Products (ATMPs) make their way from the laboratory to the patient. In this recorded session, experts discuss the Hospital Exemption as a practical pathway for ATMP delivery. Whether you're a healthcare professional, researcher, policymaker, or simply curious about the future of medical innovation, this talk offers valuable insights into how cross-sector collaboration can shape access to advanced therapies.
About ATMP Newsletter
The CREATIC ATMP Newsletter is a joint effort by Masaryk University and the University of Copenhagen. MUNI | CREATIC (Masaryk University) has established a partnership with the University of Copenhagen, Leipzig University, and the Fraunhofer Institute for Cell Therapy and Immunology IZI to build a center of excellence in research and development focused on Advanced Therapy Medicinal Products (ATMPs). This Czech‑Danish collaboration behind the newsletter brings key updates, expert perspectives, and relevant regulatory developments in the ATMP and rare disease ecosystem, with a focus on Central Europe.
Highlights from the Latest Issue
Europe Leads in Cancer-Related Startups, but Faces Scaling Challenges
Unregulated cell therapies are being sold in Europe
New EMA Guideline relevant for developers and researchers of ATMPs
In this third edition of the CREATIC ATMP Newsletter, we explore how Central European countries are cultivating stronger ecosystems for the development, regulation, and delivery of ATMPs. Jakob Wested (University of Copenhagen) shares reflections on how collaborative efforts can address fragmented health systems, strengthen clinical networks, and promote access to innovative therapies. You’ll also find highlights on the challenges of scaling cancer-related biotech startups, the rise of unregulated cell therapies in Europe, and a summary of the new EMA guideline for developers and researchers. Together, these insights help shed light on the broader landscape of advanced therapies – from policy to practice.
ATMP Newsletter Archive
Browse previous editions of the CREATIC ATMP Newsletter and stay informed about key developments in advanced therapies.
Issue #1 (online) | DOWNLOAD .pdf | Issue #2 (online) | DOWNLOAD .pdf
Stay in the Loop!
Get quartely updates on advanced therapies, expert insights, and cross-border collaboration - straight to your inbox.
Partners in Consortium
